BMO cuts BioNTech price target to $105 from $128
BMO Capital cut its BioNTech price target to $105.00 per share from $128.00, according to Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.